J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

The launch of artificial intelligence-powered imaging and mapping capabilities for electrophysiology, early momentum for a drug releasing system for bladder cancer treatment, and progress toward a table-integrated robotic surgical system are among the latest innovations from pharmaceuticals and MedTech company Johnson & Johnson.

Johnson & Johnson Chairman and CEO Joaquin Duato highlighted these products Wednesday (July 15) during the company’s second-quarter earnings call.

“Our progress in Q2 reflects what makes Johnson & Johnson unique, a company innovating across the full spectrum of healthcare, delivering strong performance today while building a pipeline that will transform care for patients tomorrow,” Duato said. “As we look ahead, our confidence is rooted in the breadth of our innovation, from transformational medicines to next-generation medical technologies.”

Johnson & Johnson announced in April that with its launch of Cartosound Sonata, it was bringing new AI-based imaging and mapping capabilities to electrophysiology. This tool uses AI to create maps that help physicians build accurate models of multiple heart chambers and to help physicians treat a range of heart rhythm conditions.

Duato said during Wednesday’s call that this tool delivers new capabilities and further strengthens the company’s position in MedTech.

The company announced in September 2025 that it secured Food and Drug Administration (FDA) approval for Inlexzo, a drug releasing system that provides extended local delivery of a cancer medication into the bladder. Johnson & Johnson said at the time in a press release that this system provides a “potential practice-changing treatment” for certain patients.

During Wednesday’s call, Duato said Johnson & Johnson is “encouraged by the early momentum” of sales of the product.

Duato also highlighted a table-integrated robotic surgical system called Ottava, saying that Johnson & Johnson is progressing toward potential FDA authorization of this system and that the system “is one of the most significant MedTech innovations we will bring to market this decade.”

“In surgery, we are unlocking a new era powered by robotics and digital innovation,” Duato said during the call.

During the second quarter, Johnson & Johnson saw operational sales growth of 5.6% to $25.3 billion, with its Innovative Medicine business up 6.8% to $16.4 billion and its MedTech business up 3.6% to $8.9 billion, according to a Wednesday earnings release.

The company raised its guidance and expects to expects to surpass $100 billion in annual revenue this year, for the first time in Johnson & Johnson’s 140-year history, Duato said.